Complement in Lupus Nephritis: New Perspectives

Overview

Journal Kidney Dis (Basel)

Specialty Nephrology

Date 2016 Aug 19

PMID 27536669

Citations 41

Authors

Lihua Bao

Patrick N Cunningham

Richard J Quigg

Affiliations

Soon will be listed here.

Abstract

Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by loss of tolerance to self-antigens, the production of autoantibodies and deposition of complement-fixing immune complexes (ICs) in injured tissues. SLE is characterized by a wide range of clinical manifestations and targeted organs, with lupus nephritis being one of the most serious complications. The complement system consists of three pathways and is tightly controlled by a set of regulatory proteins to prevent injudicious complement activation on host tissue. The involvement of the complement system in the pathogenesis of SLE is well accepted; yet, its exact role is still not clear.

Summary: Complement plays dual roles in the pathogenesis of SLE. On the one hand, the complement system appears to have protective features in that hereditary homozygous deficiencies of classical pathway components, such as C1q and C4, are associated with an increased risk for SLE. On the other hand, IC-mediated activation of complement in affected tissues is clearly evident in both experimental and human SLE along with pathological features that are logical consequences of complement activation. Studies in genetically altered mice have shown that lack of complement inhibitors, such as complement factor H (CFH) or decay-accelerating factor (DAF) accelerates the development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Crry-Ig, CR2-Crry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions.

Key Messages: SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.

Citing Articles

Exploring the causal effect of complement and IgA nephropathy-a Mendelian randomization study.

Xu H, Zou M, Cheng Y, Ge S Ren Fail. 2024; 46(2):2436632.

PMID: 39627156 PMC: 11616755. DOI: 10.1080/0886022X.2024.2436632.

Serum IFN-γ Predicts the Therapeutic Effect of Belimumab in Refractory Lupus Nephritis Patients.

Liu S, Li J, Zhang Z, Meng D, Wang K Pharmgenomics Pers Med. 2024; 17:443-452.

PMID: 39376665 PMC: 11457469. DOI: 10.2147/PGPM.S476308.

Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus.

Nicola S, Borrelli R, Corradi F, Lo Sardo L, Badiu I, Romito A Front Immunol. 2024; 15:1390642.

PMID: 39221240 PMC: 11361985. DOI: 10.3389/fimmu.2024.1390642.

Kleer J, Klehr J, Dubler D, Infanti L, Chizzolini C, Huynh-Do U Front Immunol. 2024; 15:1447991.

PMID: 39136026 PMC: 11317429. DOI: 10.3389/fimmu.2024.1447991.

Clinical Relevance of Anti-C3 and Anti-C4 Autoantibodies in Lupus Nephritis.

Vasilev V, Artero M, Petkova M, Mihaylova G, Dragon-Durey M, Radanova M Kidney Int Rep. 2024; 9(5):1429-1440.

PMID: 38707805 PMC: 11068950. DOI: 10.1016/j.ekir.2024.01.052.

References

Jonsen A, Nilsson S, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson K . Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(6):R206. PMC: 3334659. DOI: 10.1186/ar3539. View

Mathieu M, Sawyer N, Greig G, Hamel M, Kargman S, Ducharme Y . The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett. 2005; 100(2):139-45. DOI: 10.1016/j.imlet.2005.03.003. View

Brodsky R, Young N, Antonioli E, Risitano A, Schrezenmeier H, Schubert J . Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 111(4):1840-7. DOI: 10.1182/blood-2007-06-094136. View

Wenderfer S, Soimo K, Wetsel R, Braun M . Analysis of C4 and the C4 binding protein in the MRL/lpr mouse. Arthritis Res Ther. 2007; 9(5):R114. PMC: 2212569. DOI: 10.1186/ar2320. View

Lazar H, Bokesch P, van Lenta F, Fitzgerald C, Emmett C, Marsh Jr H . Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation. 2004; 110(11 Suppl 1):II274-9. DOI: 10.1161/01.CIR.0000138315.99788.eb. View

Bao L, Haas M, Quigg R . Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2010; 22(2):285-95. PMC: 3029901. DOI: 10.1681/ASN.2010060647. View

Nielsen C, Ostergaard O, Stener L, Iversen L, Truedsson L, Gullstrand B . Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum. 2012; 64(4):1227-36. DOI: 10.1002/art.34381. View

Schifferli J, Ng Y, PETERS D . The role of complement and its receptor in the elimination of immune complexes. N Engl J Med. 1986; 315(8):488-95. DOI: 10.1056/NEJM198608213150805. View

Alegretti A, Schneider L, Piccoli A, Monticielo O, Lora P, Tavares Brenol J . Diminished expression of complement regulatory proteins on peripheral blood cells from systemic lupus erythematosus patients. Clin Dev Immunol. 2012; 2012:725684. PMC: 3385850. DOI: 10.1155/2012/725684. View

10.

Kim Y, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner L . Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995; 181(1):151-9. PMC: 2191854. DOI: 10.1084/jem.181.1.151. View

11.

Degn S, Jensenius J, Thiel S . Disease-causing mutations in genes of the complement system. Am J Hum Genet. 2011; 88(6):689-705. PMC: 3113252. DOI: 10.1016/j.ajhg.2011.05.011. View

12.

Wilson J, Ratnoff W, Schur P, Fearon D . Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 1986; 29(6):739-47. DOI: 10.1002/art.1780290606. View

13.

Watanabe H, Garnier G, Circolo A, Wetsel R, Ruiz P, Holers V . Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000; 164(2):786-94. DOI: 10.4049/jimmunol.164.2.786. View

14.

Craig T, Levy R, Wasserman R, Bewtra A, Hurewitz D, Obtulowicz K . Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801-8. DOI: 10.1016/j.jaci.2009.07.017. View

15.

Gullstrand B, Martensson U, Sturfelt G, Bengtsson A, Truedsson L . Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol. 2009; 156(2):303-11. PMC: 2759479. DOI: 10.1111/j.1365-2249.2009.03896.x. View

16.

Bao L, Osawe I, Puri T, Lambris J, Haas M, Quigg R . C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005; 35(8):2496-506. DOI: 10.1002/eji.200526327. View

17.

Yin Y, Wu X, Shan G, Zhang X . Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012; 21(10):1088-97. DOI: 10.1177/0961203312451202. View

18.

Elliott M, Jarmi T, Ruiz P, Xu Y, Holers V, Gilkeson G . Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2003; 65(1):129-38. DOI: 10.1111/j.1523-1755.2004.00371.x. View

19.

Manderson A, Botto M, Walport M . The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004; 22:431-56. DOI: 10.1146/annurev.immunol.22.012703.104549. View

20.

Hillmen P, Muus P, Roth A, Elebute M, Risitano A, Schrezenmeier H . Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013; 162(1):62-73. PMC: 3744747. DOI: 10.1111/bjh.12347. View